Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

154.58
-0.3500-0.23%
Post-market: 153.90-0.6801-0.44%19:57 EDT
Volume:8.64M
Turnover:1.33B
Market Cap:371.93B
PE:17.20
High:154.90
Open:154.32
Low:152.45
Close:154.93
Loading ...

Johnson & Johnson's Third Bankruptcy Case for Talc Lawsuits Thrown Out -- WSJ

Dow Jones
·
01 Apr

FACTBOX-Trump's tariffs and threatened trade actions

Reuters
·
01 Apr

JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

Zacks
·
31 Mar

Pharma Stocks Sink After Ouster of Top FDA Vaccine Regulator

Reuters
·
31 Mar

1 Healthcare Stock to Target This Week and 2 to Turn Down

StockStory
·
31 Mar

Jim Cramer on Johnson & Johnson (NYSE:JNJ): Their Spinoff Was Ill-Advised

Insider Monkey
·
29 Mar

Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case

Reuters
·
29 Mar

Johnson & Johnson Unit Ordered to Pay US About $1.64 Billion in HIV Drug Marketing Case

MT Newswires Live
·
29 Mar

JNJ Unit Ordered to Cough Up $1.64B for Illegal Promotion of HIV Drugs

TIPRANKS
·
29 Mar

Press Release: LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Dow Jones
·
28 Mar

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

GlobeNewswire
·
28 Mar

Johnson & Johnson (NYSE:JNJ) Presents Promising Nipocalimab Data At AAN Annual Meeting

Simply Wall St.
·
28 Mar

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Siemens Healthineers AG (OtherSEMHF)

TIPRANKS
·
27 Mar

2 Recession-Proof Dividend Stocks to Buy and Hold

Motley Fool
·
27 Mar

Jefferies profit misses estimates as bond trading, equity underwriting weaken

Reuters
·
27 Mar

AnaptysBio could have positive read from J&J abstracts, says Guggenheim

TIPRANKS
·
27 Mar

Jim Cramer Highlights Johnson & Johnson (JNJ) as a Rare Winner Amid Market Sell-Off

Insider Monkey
·
27 Mar

BRIEF-J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib

Reuters
·
27 Mar

Johnson & Johnson Reports Positive Data from Phase 3 Study of Lung Cancer Drug Candidate

MT Newswires Live
·
27 Mar

J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study

TIPRANKS
·
26 Mar